Last reviewed · How we verify
dihydroartemisinin plus piperaquine
Dihydroartemisinin is a derivative of artemisinin that kills malaria parasites by generating free radicals, while piperaquine acts as a blood schizonticide.
Dihydroartemisinin is a derivative of artemisinin that kills malaria parasites by generating free radicals, while piperaquine acts as a blood schizonticide. Used for Uncomplicated malaria, Severe malaria.
At a glance
| Generic name | dihydroartemisinin plus piperaquine |
|---|---|
| Also known as | Duo cotexcin |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Antimalarial |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Dihydroartemisinin works by generating free radicals that damage the malaria parasite's cell membrane, ultimately leading to its death. Piperaquine, on the other hand, targets the parasite's liver stages and prevents its re-emergence. This combination therapy is effective against both the blood and liver stages of the malaria parasite.
Approved indications
- Uncomplicated malaria
- Severe malaria
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
Key clinical trials
- A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults (PHASE1)
- Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria (PHASE4)
- Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana (NA)
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- Mass Vaccine and Drug Administration, Bangladesh (PHASE4)
- Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials (PHASE2, PHASE3)
- MDA and Targeted Control Against Plasmodium Carriage in the Sahel (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: